Status: Recruiting
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
The goal of this study is to evaluate the efficacy and safety of Ivonescimab in participants with advanced, metastatic salivary gland cancers. The name of the study drug involved in this study is: -Ivonescimab (a type of antibody)
Participants needed: 35
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Glenn J. HannaUpdated: Jul 29, 2025Locations: 2
Eligibility criteria
Participants must have histologically confirmed salivary gland carcinoma (any hi... [+18]
Participant has known active central nervous system (CNS) metastases and/or carc... [+18]